The iTind procedure reshapes the anatomy of the prostatic urethra, gently creating a wider opening for urine to flow freely, without burning or cutting out tissue, and without leaving behind a permanent implant. The treatment is straightforward, does not require overnight hospitalisation, and has none of the side effects associated with prescription medication. Additionally, one of the main advantages of the iTind procedure is the preservation of sexual and ejaculatory functions2, 3, 4.
Dr Kooner is pleased to be one of the first Urologists in Australia to perform the iTind procedure to treat men with the symptoms of enlarged prostate. The iTind procedure is a new minimally invasive therapy for benign prostatic hyperplasia (BPH), offering an alternative to surgery, drugs, and permanent implants.
Dr Kooner has been implanting iTind since September 2022, he says "The iTind is an important addition to our treatment portfolio, offering a less invasive treatment option with no major side effects."1
The iTind procedure reshapes the anatomy of the prostatic urethra, gently creating a wider opening for urine to flow freely, without burning or cutting out tissue, and without leaving behind a permanent implant. The treatment is straightforward, does not require overnight hospitalisation, and has none of the side effects associated with prescription medication. Additionally, one of the main advantages of the iTind procedure is the preservation of sexual and ejaculatory functions2, 3, 4.
Having performed the iTind procedure on many patients to date. Dr Kooner says it is a promising procedure providing relief for BPH patients.
References
1 Kadner G, Valerio M, Giannakis I, Manit A, Lumen N, Ho BSH, Alonso S, Schulman C, Barber N, Amparore D, Porpiglia F. Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study. World J Urol. 2020 Mar 2. PMID: 32124019
2. Chughtai B, Elterman D, Shore N, et al. The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial [published online ahead of print, 2020 Dec 26].Urology. 2020;S0090-4295(20)31520-X. doi:10.1016/j.urology.2020.12.022
3. De Nunzio C, Cantiello F, Fiori C, et al. Urinary and sexual function after treatment with temporary implantable nitinol device (iTind) in men with LUTS: 6-month interim results of the MT-06-study. World J Urol. 2021;39(6):2037-2042. doi:10.1007/s00345-020-03418-2
4. Elterman D, Alshak M, Martinez Diaz S, et al. An Evaluation of Sexual Function in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia in Men Treated with the Temporarily Implanted Nitinol Device [published online ahead of print, 2022 Sep 7]. J Endourol. 2022; doi:10.1089/end.2022.0226